Ophthalmic drug development: Procedural considerations

被引：0
|
作者：
Novack, GD [1 ]
机构：
[1] Pharmalog Dev Inc, San Rafael, CA 94903 USA
来源：
JOURNAL OF GLAUCOMA | 1998年 / 7卷 / 03期
关键词：
investigational new drug; new drug application; drug development; glaucoma; adverse event;
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：202 / 209
页数：8
相关论文
共 50 条
  • [1] Ophthalmic Drug Delivery: Development and Regulatory Considerations
    Novack, G. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) : 539 - 543
  • [2] Ophthalmic Drug Discovery and Development
    Gukasyan, Hovhannes J.
    Hailu, Shumet
    Karami, Thomas K.
    PHARMACEUTICAL RESEARCH, 2019, 36 (05)
  • [3] Ophthalmic Drug Discovery and Development
    Hovhannes J. Gukasyan
    Shumet Hailu
    Thomas K. Karami
    Pharmaceutical Research, 2019, 36
  • [4] PRACTICAL ASPECTS OF OPHTHALMIC DRUG DEVELOPMENT
    AKERS, MJ
    SCHOENWALD, RD
    MCGINITY, JW
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1977, 3 (03) : 185 - 217
  • [5] Procedural Considerations
    Baddeley, Robin
    Aabakken, Lars
    Veitch, Andrew
    Hayee, Bu'hussain
    GASTROENTEROLOGY, 2022, 162 (06) : 1557 - 1557
  • [6] Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology
    Cheryl L. Rowe-Rendleman
    Pharmaceutical Research, 2019, 36
  • [7] Considerations for Ophthalmic Complications
    Hussain, Ahsen
    JAMA FACIAL PLASTIC SURGERY, 2019, 21 (02) : 171 - 172
  • [8] Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology
    Rowe-Rendleman, Cheryl L.
    PHARMACEUTICAL RESEARCH, 2019, 36 (04)
  • [9] Development of an In Vitro Blink Model for Ophthalmic Drug Delivery
    Chau-Minh Phan
    Shukla, Manish
    Walther, Hendrik
    Heynen, Miriam
    Suh, David
    Jones, Lyndon
    PHARMACEUTICS, 2021, 13 (03) : 1 - 10
  • [10] Eyes on New Product Development: Ophthalmic Drug Delivery
    Novack, Gary D.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (02) : 90 - 91
12345